公司擁有ABGENT、B-bridge、IBL-America、R&D、CST、MBL、SAB、KPL、Santa、Abnova、LifeSpan等AF555標(biāo)記的磷酸化FMS樣酪氨酸激酶3品牌全年代理權(quán)，價(jià)格行業(yè)優(yōu)勢(shì)明顯。
英文名稱 Anti-Phospho-FLT3 （Tyr589/591）/AF555
中文名稱 AF555標(biāo)記的磷酸化FMS樣酪氨酸激酶3
別 名 CD135 antigen; Fetal liver kinase 2; FL cytokine receptor; Flk 2; Flk2; Flt 3; Flt3; FMS like tyrosine kinase 3; Fms related tyrosine kinase 3; Growth factor receptor tyrosine kinase type III; Stem cell tyrosine kinase 1; Stk 1; Stk1; Tyrosine protein kinase receptor FLT3; FLT3_HUMAN.
濃 度 2mg/1ml
規(guī) 格 100ug
抗體來(lái)源 Rabbit
克隆類型 polyclonal
產(chǎn)品類型 標(biāo)記一抗 磷酸化抗體
研究領(lǐng)域 激酶和磷酸酶
31895蔗糖Sucrose57-50-1C12H22O11342.3100mg
31896耐斯糖Nystose 13133-07-8C24H42O21666.5820mg
31897苦杏仁苷Amygdalin29883-15-6C20H27457.4320mg
31898扁桃酸Mandelic acid611-71-2C8H8O3152.1520mg
31899長(zhǎng)春新堿Vincristine57-22-7C46H56N4O10824.9620mg
31900長(zhǎng)春花堿Vinblastine865-21-4C46H58N4O9810.9720mg
31901長(zhǎng)春質(zhì)堿Catharanthine2468-21-5C21H24N2O2336.4320mg
31902文多靈Vindoline2182-14-1C25H32N2O6456.5320mg
31903長(zhǎng)春瑞濱VINORELBINE71486-22-1"C45H54N4O8
"778.9420mg
31904長(zhǎng)春胺Vincamine"1617-90-9
""C21H26N2O3
"354.4420mg
31905長(zhǎng)春西汀Vinpocetine42971-09-5C22H26N2O2350.4620mg
31906川續(xù)斷皂苷乙Dipsacoside B33289-85-9C53H86O221075.2420mg
31907川續(xù)斷皂苷ⅥAkebia saponin D39524-08-8C47H76O18 929.09920mg
31908橙皮苷Hesperidin520-26-3C28H34O15610.5620mg
31909橙皮素"Hesperetin
"520-33-2C16H14O6302.2820mg
31910橘皮素Tangeretin481-53-8C20H20O7372.3720mg
31911甲基橙皮苷（95%）Methyl hesperidin11013-97-1C29H36O15624.5920mg
31912新橙皮苷二氫查爾酮Neosperidin dihydrochalcone 20702-77-6C28H36O15612.5820mg
31913新橙皮苷Neohesperidin13241-33-3C28H34O15610.5620mg
31914異鼠李素-3-O-新橙皮苷Isorhamnetin-3-O-nehesperidine55033-90-4C28H32O16 20mg
31915香蒲新苷Typhaneoside104472-68-6C34H42O20770.68620mg
31916橙黃決明素Aurantio-obtusin67979-25-3C17H14O7330.29120mg
31917刺五加苷EEleutheroside E39432-56-9C34H46O18742.7220mg
31918刺五加苷BEleutheroside B 118-34-3C17H24O9372.3720mg
31919胡蘿卜苷Eleutheroside A474-58-8C35H60O6576.8520mg
31920β-胡蘿卜素β-Carotene7235-40-7C40H56536.8720mg
31921葉黃素（90%）Xanthophyll127-40-2C40H56O2568.8720mg
31922穿心蓮內(nèi)酯Andrographolide5508-58-7C20H30O5350.4520mg
31923穿心蓮新苷 neoandrographolide27215-14-1C26H40O8480.59120mg
31924脫水穿心蓮內(nèi)酯（99%）Dehydroandrographolide134418-28-3C20H28O5348.4320mg
31925穿琥寧Kalii Dehydrographolidi SuccinasC28H35KO10570.6820mg
31926淫羊藿苷Icariin489-32-7C33H40O15676.6620mg
31927朝藿定CEpmedin C110642-44-9C39H50O19822.820mg
31928朝藿定BEpmedin B110623-73-9C38H48O19808.7820mg
31929朝藿定AEpimedin A110623-72-8C39H50O19822.820mg
31930朝藿定A1Epimedin A1140147-77-9C39H50O20838.80410mg
31931寶藿苷ⅠBaohuoside I113558-15-9C27H30O10 514.5220mg
31932淫羊藿次苷I（95%）Icarisid I C27H30O11 530.5220mg
31933脫水淫羊藿素Anhydroicaritin 38226-86-7C21H20O6 368.3820mg
31934淫羊藿素Oxypeucedanin737-52-0C16H14O5286.2820mg
31935川陳皮素Naringin10236-47-2C27H32O14580.5320mg
31936去甲基川陳皮素Demethylnobiletin2174-59-6C20H20O8 388.3710mg
31937刺芒柄花素Formononetin485-72-3C16H12O4268.2720mg
蛋白分子量 predicted molecular weight: 109kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated Synthesised phosphopeptide derived from human FLT3 around the phosphorylation site of Tyr589/591
亞 型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4.
產(chǎn)品應(yīng)用 IF=1:50-200
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 CD135 is a tyrosine kinase receptor expressed on normal cells including CD34+ hematopoietic stem cells, myelomonocytic progenitors, primitive B cell progenitors, and thymocytes. CD135 is also expressed on malignant hematopoietic cells including AML, ALL and CML BC. CD135, also known as FMS-like tyrosine kinase 3, FLT3, STK1, and Flk2, is a growth factor receptor that binds the FLT3 ligand to promote the growth and differentiation of primitive hematopoietic cells. The intracytoplasmic domain of CD135 is modified by phosphorylation and has been shown to interact with Grb2, SOCS1, VAV1, and Shc. In humans, expression of Flt3 is restricted to subsets of CD34 positive as well as CD34 negative normal bone marrow cells. In these cells, the level of expression of Flt3 is rather low. Most of the CD34 bright Flt3+ cells co-express CD117 at high levels. They may represent early cycling, but not quiescent stem cells. Flt3+ cells in the CD34lo and CD34- populations do not co-express CD117 molecule and may represent B lymphoid precursors.
Function : Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways.
Subunit : Monomer in the absence of bound FLT3LG. Homodimer in the presence of bound FLT3LG. One homodimer interacts with one FLT3LG molecule. Interacts with FIZ1 following ligand activation （By similarity）. Interacts with FES, FER and GRB2. Interacts with PTPRJ/DEP-1 and PTPN11/SHP2.
Subcellular Location : Membrane; Single-pass type I membrane protein. Endoplasmic reticulum lumen.
Tissue Specificity : Detected in bone marrow, in hematopoietic stem cells, in myeloid progenitor cells and in granulocyte/macrophage progenitor cells （at protein level）. Detected in bone marrow, liver, thymus, spleen and lymph node, and at low levels in kidney and pancreas. Highly expressed in T-cell leukemia.
Post-translational modifications : N-glycosylated, contains complex N-glycans with sialic acid.
Autophosphorylated on several tyrosine residues in response to FLT3LG binding. FLT3LG binding also increases phosphorylation of mutant kinases that are constitutively activated. Dephosphorylated by PTPRJ/DEP-1, PTPN1, PTPN6/SHP-1, and to a lesser degree by PTPN12. Dephosphorylation is important for export from the endoplasmic reticulum and location at the cell membrane.
DISEASE : Defects in FLT3 are a cause of acute myelogenous leukemia （AML） [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development. Note=Somatic mutations that lead to constitutive activation of FLT3 are frequent in AML patients. These mutations fall into two classes, the most common being in-frame internal tandem duplications of variable length in the juxtamembrane region that disrupt the normal regulation of the kinase activity. Likewise, point mutations in the activation loop of the kinase domain can result in a constitutively activated kinase.
Similarity : Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 1 Ig-like C2-type （immunoglobulin-like） domain.
Contains 1 protein kinase domain.